Back to Awarded Treatment Trials


Awarded Trial: 05T-678

Grant ID

05T-678

Illness

Schizophrenia

Primary Drug/Intervention

Cannabidiol

Primary Dosage

200 mg t.i.d.

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Leweke

Sample Size

16

Duration of Study Period for Each Subject

31 days

Outcome Measurements

PANSS, BPRS, CGI, BDIS, Quality of life scale, SAS

Results

Twenty-nine (29) individuals with acute schizophrenia were randomized to cannabidiol 600 mg/d or placebo for 14 days, then crossed over to the other treatment for 14 days. Assessments were done with BPRS, PANSS, CGI, HAM-A, and CDSS. Individuals on cannabidiol showed greater improvement, but it did not achieve statistical significance.

Publication

N/A

Link

N/A

PI Name

Franz-Markus Leweke

Degree

MD

Center

Department of Psychiatry and Psychotherapy

Institution

Klinikum der Unversitaet zu Koeln

Address

Kerpener Str. 62

City or Town

Koeln

State or Province

N/A

Zip or Postal Code

50937

Country

Germany

Email Address

m.leweke@uni.de